A late-onset congenital myasthenic syndrome due to a heterozygous DOK7 mutation

被引:5
|
作者
Bastos, Paulo [1 ]
Barbosa, Raquel [2 ]
Fernandes, Marco [2 ]
Alonso, Isabel [3 ,4 ,5 ]
机构
[1] Inst Pasteur, Unite Biol & Genet Paroi Bacterienne, Paris, France
[2] Ctr Hosp Lisboa Ocidental, Hosp Egas Moniz, Dept Neurol, Lisbon, Portugal
[3] Inst Mol & Cellular Biol IBMC, Ctr Predict & Prevent Genet CGPP, Porto, Portugal
[4] Univ Porto, 3S Inst Invest & Innovat Hlth, Porto, Portugal
[5] Univ Porto, IBMC Inst Mol & Cell Biol, UnIGENe Unit Genet & Epidemiol Res Neurol Dis, Porto, Portugal
关键词
Myasthenia gravis; DOK7; Congenital myasthenic syndromes; Neuromuscular junction; Repetitive Nerve Stimulation; UNDERLIE; SPECTRUM; CHANNEL; MUSCLE;
D O I
10.1016/j.nmd.2020.02.009
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Congenital myasthenic syndromes are disorders of the neuromuscular junction resulting from genetic defects in its components. Clinical presentations are diverse and virtually always of early onset. We report a 67-year-old female patient first presenting with episodes of sudden respiratory failure. A diagnosis of seronegative myasthenia gravis was put forward based on the presence of a limb-girdle pattern of muscle weakness with pathological decremental responses on Repetitive Nerve Stimulation. Lack of response to steroids, intravenous human immunoglobulin and acetylcholinesterase inhibitors lead us to test for classical congenital myasthenic syndrome genes. A c.1378dup heterozygotic mutation in DOK7 was found, classically (albeit not exclusively) described as pathogenic only when inherited in a homozygotic fashion. Patients with such a single, heterozygous mutation have been previously described, but these have been left unexplained. Thus, under certain still poorly understood circumstances, a heterozygotic state may allow for disease manifestation. These patients may benefit from tailored therapies akin to those normally reserved to homozygotic/compound heterozygotic patients. Awareness for and recognition of such conditions are expected to allow for better provided care and improved quality of life. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码:331 / 335
页数:5
相关论文
共 50 条
  • [1] Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation
    Lorenzoni, Paulo J.
    Scola, Rosana H.
    Kay, Claudia S. K.
    Filla, Luciane
    Miranda, Anna P. P.
    Pinheiro, Joao M. R.
    Chaouch, Amina
    Lochmueller, Hanns
    Werneck, Lineu C.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 331 (1-2) : 155 - 157
  • [2] DOK7 congenital myasthenic syndrome
    Palace, Jacqueline
    MYASTHENIA GRAVIS AND RELATED DISORDERS II, 2012, 1275 : 49 - 53
  • [3] A novel mutation in a patient with a DOK7 congenital myasthenic syndrome
    Willis, T.
    Kulshrestha, R.
    Sewry, C.
    Palace, J.
    Liu, W.
    Beeson, D.
    NEUROMUSCULAR DISORDERS, 2015, 25 : S210 - S210
  • [4] Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7
    Lashley, D.
    Palace, J.
    Jayawant, S.
    Robb, S.
    Beeson, D.
    NEUROLOGY, 2010, 74 (19) : 1517 - 1523
  • [5] Congenital myasthenic syndrome and minicore-like myopathy with DOK7 mutation
    Lorenzoni, Paulo Jose
    Scola, Rosana Herminia
    Kamoi, Claudia S.
    Lochmueller, Hanns
    Werneck, Lineu Cesar
    MUSCLE & NERVE, 2013, 48 (01) : 151 - 152
  • [6] Therapeutic effects of ephedrine in congenital myasthenic syndrome due to DOK7 mutations
    Schara, U.
    Deschauer, M.
    Wendt, M.
    Strigi-Pill, N.
    Mueller, J.
    Abicht, A.
    Lochmueller, H.
    NEUROMUSCULAR DISORDERS, 2007, 17 (9-10) : 818 - 819
  • [7] Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations
    Burke, Georgina
    Hiscock, Andrew
    Klein, Andrea
    Niks, Erik H.
    Main, Marion
    Manzur, Adnan Y.
    Ng, Joanne
    de Vile, Catherine
    Muntoni, Francesco
    Beeson, David
    Robb, Stephanie
    NEUROMUSCULAR DISORDERS, 2013, 23 (02) : 170 - 175
  • [8] Diagnosis of DOK7 Congenital Myasthenic Syndrome during pregnancy
    Fernandes, M.
    Caetano, A.
    Pinto, M.
    Medeiros, E.
    Nogueira dos Santos, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 288 - 288
  • [9] DOK7 congenital myasthenic syndrome responsive to oral salbutamol
    Tayade, K.
    Salunkhe, M.
    Agarwal, A.
    Radhakrishnan, D. M.
    Srivastava, A. K.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2022, 115 (05) : 323 - 324
  • [10] Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations
    Schara, U.
    Barisic, N.
    Deschauer, M.
    Lindberg, C.
    Straub, V.
    Strigl-Pill, N.
    Wendt, M.
    Abicht, A.
    Mueller, J. S.
    Lochmueller, H.
    NEUROMUSCULAR DISORDERS, 2009, 19 (12) : 828 - 832